HRP20110094T1 - Čvrsti pripravak koji sadrži alogliptin i pioglitazon - Google Patents
Čvrsti pripravak koji sadrži alogliptin i pioglitazon Download PDFInfo
- Publication number
- HRP20110094T1 HRP20110094T1 HR20110094T HRP20110094T HRP20110094T1 HR P20110094 T1 HRP20110094 T1 HR P20110094T1 HR 20110094 T HR20110094 T HR 20110094T HR P20110094 T HRP20110094 T HR P20110094T HR P20110094 T1 HRP20110094 T1 HR P20110094T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid preparation
- sugar
- excipient
- preparation according
- pioglitazone
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims 8
- LNTORSITGSWVNQ-DYYGGQLPSA-N 2-[[6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile;5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 LNTORSITGSWVNQ-DYYGGQLPSA-N 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 7
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract 5
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- ZSBOMTDTBDDKMP-UHFFFAOYSA-N 2-[[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCCC(N)C1 ZSBOMTDTBDDKMP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960005095 pioglitazone Drugs 0.000 claims abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Čvrsti pripravak, naznačen time, da sadrži sljedeći prvi i drugi dio: (1) prvi dio koji sadrži 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-diokso-1(2H)-pirimidinil]metil]-benzonitril ili njegovu sol te kao prvi ekscipijent, šećer ili šećerni alkohol; i (2) drugi dio koji sadrži pioglitazon ili njegovu sol te kao drugi ekscipijent, šećer ili šećerni alkohol. Patent sadrži još 6 patentnih zahtjeva.
Claims (7)
1. Čvrsti pripravak, naznačen time, da sadrži sljedeći prvi i drugi dio:
(1) prvi dio koji sadrži 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-diokso-1(2H)-pirimidinil]metil]-benzonitril ili njegovu sol te kao prvi ekscipijent, šećer ili šećerni alkohol; i
(2) drugi dio koji sadrži pioglitazon ili njegovu sol te kao drugi ekscipijent, šećer ili šećerni alkohol.
2. Čvrsti pripravak prema zahtjevu 1, naznačen time, da šećer ili šećerni alkohol je laktoza, sukroza, eritritol ili manitol.
3. Čvrsti pripravak prema zahtjevu 2, naznačen time, da prvi i drugi ekscipijent je manitol.
4. Čvrsti pripravak prema zahtjevu 3, naznačen time, da je to prevučena tableta koja sadrži unutarnju jezgru načinjenu od prvog dijela, te vanjski sloj načinjen od drugog dijela.
5. Čvrsti pripravak prema zahtjevu 2, naznačen time, da prvi ekscipijent je manitol, a drugi ekscipijent je laktoza.
6. Čvrsti pripravak prema zahtjevu 5, naznačen time, da je to prevučena tableta koja sadrži unutarnju jezgru načinjenu od drugog dijela, te vanjski sloj načinjen od prvog dijela.
7. Čvrsti pripravak prema zahtjevu 5, naznačen time, da je to višeslojna tableta koja sadrži prvi sloj načinjen od prvog dijela, i drugi sloj koji je načinjen od drugog dijela.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007023594 | 2007-02-01 | ||
PCT/JP2008/051900 WO2008093882A1 (en) | 2007-02-01 | 2008-01-30 | Solid preparation comprising alogliptin and pioglitazone |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20110094T1 true HRP20110094T1 (hr) | 2011-03-31 |
HRP20110094T8 HRP20110094T8 (hr) | 2011-07-31 |
Family
ID=39240362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110094T HRP20110094T8 (hr) | 2007-02-01 | 2011-02-07 | Čvrsti pripravak koji sadrži alogliptin i pioglitazon |
Country Status (39)
Country | Link |
---|---|
US (1) | US8637079B2 (hr) |
EP (1) | EP2107905B1 (hr) |
JP (1) | JP5284968B2 (hr) |
KR (1) | KR101486091B1 (hr) |
CN (1) | CN101646420B (hr) |
AR (1) | AR065097A1 (hr) |
AT (1) | ATE488227T1 (hr) |
AU (1) | AU2008211981B2 (hr) |
BR (1) | BRPI0807453B8 (hr) |
CA (1) | CA2677201C (hr) |
CL (1) | CL2008000279A1 (hr) |
CR (1) | CR10992A (hr) |
CY (1) | CY1111264T1 (hr) |
DE (1) | DE602008003522D1 (hr) |
DK (1) | DK2107905T3 (hr) |
DO (1) | DOP2009000195A (hr) |
EA (1) | EA015180B1 (hr) |
EC (1) | ECSP099608A (hr) |
ES (1) | ES2354397T3 (hr) |
GE (1) | GEP20125410B (hr) |
HK (1) | HK1138188A1 (hr) |
HR (1) | HRP20110094T8 (hr) |
IL (1) | IL200108A (hr) |
JO (1) | JO2650B1 (hr) |
MA (1) | MA31169B1 (hr) |
ME (1) | ME01239B (hr) |
MX (1) | MX2009008100A (hr) |
MY (1) | MY147596A (hr) |
NZ (1) | NZ579008A (hr) |
PE (1) | PE20081663A1 (hr) |
PL (1) | PL2107905T3 (hr) |
PT (1) | PT2107905E (hr) |
RS (1) | RS51592B (hr) |
SI (1) | SI2107905T1 (hr) |
TN (1) | TN2009000317A1 (hr) |
TW (2) | TW201350143A (hr) |
UA (1) | UA95828C2 (hr) |
WO (1) | WO2008093882A1 (hr) |
ZA (1) | ZA200905621B (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
ES2603879T3 (es) * | 2007-07-19 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Preparación sólida que comprende alogliptina e hidrocloruro de metformina |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
CA2735562C (en) | 2008-08-15 | 2017-10-17 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for wound healing |
RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
PL2395983T3 (pl) | 2009-02-13 | 2020-09-07 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania |
NZ594044A (en) | 2009-02-13 | 2014-08-29 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
JP2013512229A (ja) * | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
AU2011249771A1 (en) * | 2010-05-05 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
CN103156819A (zh) * | 2013-03-29 | 2013-06-19 | 山东罗欣药业股份有限公司 | 苯甲酸阿格列汀组合物片剂及其制备方法 |
EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
JP6027710B1 (ja) * | 2014-12-25 | 2016-11-16 | 田辺三菱製薬株式会社 | 糖尿病治療用固形製剤 |
WO2016202961A1 (en) * | 2015-06-17 | 2016-12-22 | H E X A L Aktiengesellschaft | Alogliptin formulation |
CN108289849A (zh) * | 2015-06-26 | 2018-07-17 | 韩国联合制药株式会社 | 莫沙必利与雷贝拉唑的复合制剂 |
CN105030719B (zh) * | 2015-08-20 | 2018-07-20 | 杭州成邦医药科技有限公司 | 一种含有阿格列汀和吡格列酮的组合物 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
CN113925838B (zh) * | 2021-11-11 | 2022-11-11 | 乐普制药科技有限公司 | 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
ATE116133T1 (de) | 1990-11-27 | 1995-01-15 | Byk Gulden Lomberg Chem Fab | Retardzubereitung für urapidil. |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
JP2931811B2 (ja) | 1997-06-03 | 1999-08-09 | ユニコロイド株式会社 | 徐放性カプセル |
US6030641A (en) * | 1997-06-03 | 2000-02-29 | Uni Colloid Kabushiki Kaisha | Sustained release capsule and method for preparing the same |
WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
DE19725911A1 (de) | 1997-06-13 | 1998-12-17 | Roland Prof Dr Bodmeier | Zusammensetzungen, die die Wirkstofffreisetzung verzögern |
JP2000154137A (ja) | 1998-09-18 | 2000-06-06 | Takeda Chem Ind Ltd | 徐放性経口製剤 |
WO2000016776A1 (fr) | 1998-09-18 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Preparations a administrer par voie buccale a liberation lente |
DK1133312T3 (da) * | 1999-06-21 | 2008-01-02 | Lilly Co Eli | Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
EP1741447B1 (en) | 2000-01-21 | 2013-09-18 | Novartis AG | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7078397B2 (en) * | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
AU2003281181A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
IN192749B (hr) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
MXPA05007883A (es) * | 2003-01-29 | 2005-09-21 | Takeda Pharmaceutical | Proceso para producir una preparacion recubierta. |
JP4567340B2 (ja) * | 2003-01-29 | 2010-10-20 | 武田薬品工業株式会社 | 被覆製剤の製造方法 |
NZ546337A (en) * | 2003-10-31 | 2009-03-31 | Takeda Pharmaceutical | Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80 |
JP4361461B2 (ja) | 2003-10-31 | 2009-11-11 | 武田薬品工業株式会社 | 固形製剤 |
ES2684325T5 (es) | 2004-01-20 | 2024-06-10 | Novartis Ag | Formulación y proceso de compresión directa |
CN102127057A (zh) * | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
AU2005299808B2 (en) | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
GT200600218A (es) | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
WO2007033266A2 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetis |
TW200745079A (en) | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
EP1962811B1 (en) | 2005-12-22 | 2016-04-27 | Takeda Pharmaceutical Company Limited | Solid preparation containing an insulin sensitizer |
RU2438671C2 (ru) * | 2005-12-28 | 2012-01-10 | Такеда Фармасьютикал Компани Лимитед | Терапевтическое средство против диабета |
-
2008
- 2008-01-30 JP JP2009532078A patent/JP5284968B2/ja active Active
- 2008-01-30 US US12/449,255 patent/US8637079B2/en active Active
- 2008-01-30 ES ES08704473T patent/ES2354397T3/es active Active
- 2008-01-30 EA EA200970726A patent/EA015180B1/ru active Protection Beyond IP Right Term
- 2008-01-30 ZA ZA200905621A patent/ZA200905621B/xx unknown
- 2008-01-30 TW TW102128229A patent/TW201350143A/zh unknown
- 2008-01-30 UA UAA200909031A patent/UA95828C2/ru unknown
- 2008-01-30 AR ARP080100381A patent/AR065097A1/es not_active Application Discontinuation
- 2008-01-30 MX MX2009008100A patent/MX2009008100A/es active IP Right Grant
- 2008-01-30 MY MYPI20093188A patent/MY147596A/en unknown
- 2008-01-30 CL CL200800279A patent/CL2008000279A1/es unknown
- 2008-01-30 CN CN2008800103744A patent/CN101646420B/zh active Active
- 2008-01-30 SI SI200830149T patent/SI2107905T1/sl unknown
- 2008-01-30 NZ NZ579008A patent/NZ579008A/en unknown
- 2008-01-30 EP EP08704473A patent/EP2107905B1/en active Active
- 2008-01-30 RS RS20110080A patent/RS51592B/en unknown
- 2008-01-30 BR BRPI0807453A patent/BRPI0807453B8/pt active IP Right Grant
- 2008-01-30 AU AU2008211981A patent/AU2008211981B2/en active Active
- 2008-01-30 PL PL08704473T patent/PL2107905T3/pl unknown
- 2008-01-30 GE GEAP200811445A patent/GEP20125410B/en unknown
- 2008-01-30 PE PE2008000222A patent/PE20081663A1/es active IP Right Grant
- 2008-01-30 PT PT08704473T patent/PT2107905E/pt unknown
- 2008-01-30 KR KR1020097017913A patent/KR101486091B1/ko active IP Right Review Request
- 2008-01-30 ME MEP-2011-167A patent/ME01239B/me unknown
- 2008-01-30 TW TW097103417A patent/TWI453041B/zh active
- 2008-01-30 AT AT08704473T patent/ATE488227T1/de active
- 2008-01-30 DE DE602008003522T patent/DE602008003522D1/de active Active
- 2008-01-30 DK DK08704473.1T patent/DK2107905T3/da active
- 2008-01-30 WO PCT/JP2008/051900 patent/WO2008093882A1/en active Application Filing
- 2008-01-30 CA CA2677201A patent/CA2677201C/en active Active
- 2008-02-02 JO JO200830A patent/JO2650B1/en active
-
2009
- 2009-07-28 IL IL200108A patent/IL200108A/en active IP Right Grant
- 2009-07-30 TN TNP2009000317A patent/TN2009000317A1/fr unknown
- 2009-07-31 DO DO2009000195A patent/DOP2009000195A/es unknown
- 2009-08-06 MA MA32148A patent/MA31169B1/fr unknown
- 2009-08-24 CR CR10992A patent/CR10992A/es unknown
- 2009-08-31 EC EC2009009608A patent/ECSP099608A/es unknown
-
2010
- 2010-04-13 HK HK10103605.9A patent/HK1138188A1/xx unknown
-
2011
- 2011-02-07 HR HR20110094T patent/HRP20110094T8/hr unknown
- 2011-02-09 CY CY20111100150T patent/CY1111264T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110094T1 (hr) | Čvrsti pripravak koji sadrži alogliptin i pioglitazon | |
CY1114925T1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
MX2009009703A (es) | Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo. | |
MX345777B (es) | Formulaciones de tabletas bicapa. | |
MEP18208A (hr) | Formulacije u obliku pjene kao modifikatori imunog odgovora | |
CL2007003819A1 (es) | Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades. | |
DE502005009109D1 (de) | Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
MX2007014892A (es) | Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico . | |
UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
JP2008513467A5 (hr) | ||
JP2007527914A5 (hr) | ||
CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
CU20080043A7 (es) | Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables | |
DK1725218T3 (da) | Farmaceutisk sammensætning omfattende pimobendan | |
EP2078731A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
WO2014170755A3 (en) | Sustained-release formulations of colchicine and methods of using same | |
JP2008515980A5 (hr) | ||
PE20110583A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
FR2873585B1 (fr) | Nouvelles formulations galeniques de principes actifs | |
WO2010055119A3 (en) | Pharmaceutical composition comprising pimobendan | |
MX2012001284A (es) | Tableta. | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
RS51211B (sr) | Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja | |
WO2007065625A3 (en) | Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations |